Bamlanivimab (LY-Cov555) for the Treatment of Covid-19

Image 1-Bamlanivimab (LY-Cov555)
Bamlanivimab (LY-CoV555) received emergency use authorisation for the treatment of mild to moderate COVID-19 in high-risk patients in November 2020. Credit: Eli Lilly and Company.